Navigation Links
Anthera Pharmaceuticals Forms Scientific Advisory Board

- Renowned Clinical Authorities to Advise on Development of New Drug

Candidate to Treat Autoimmune Disease -

SAN MATEO, Calif., Feb. 5 /PRNewswire/ -- Anthera Pharmaceuticals, Inc., a privately-held drug development company, announced today that it has appointed the first five members of its Scientific Advisory Board for A-623, a peptide fusion protein licensed from Amgen in December 2007 for the treatment of systemic lupus erythematosus (SLE) and other autoimmune diseases. The scientific advisory board will include Jill Buyon, M.D., Betty Diamond, M.D., Kenneth Kalunian, M.D., David Wofsy, M.D., and Debra Zack, M.D., Ph.D.

"We are pleased to have recruited such an outstanding team of internationally recognized experts in the field of autoimmune disease," said Paul F. Truex, President and Chief Executive Officer of Anthera Pharmaceuticals, Inc. "All have made significant contributions to the scientific understanding of lupus. The extraordinary magnitude of research and clinical expertise assembled on this board will be invaluable as we advance our clinical development programs for A-623."

-- Jill Buyon, M.D. is Professor of Medicine, New York University School

of Medicine and Vice Chairman of the Department of Rheumatology at NYU

Hospital for Joint Diseases.

-- Betty Diamond, M.D. is Head of The Center for Autoimmune and

Musculoskeletal Disease at the Feinstein Institute for Medical

Research and is on the faculty at Albert Einstein College of Medicine.

-- Kenneth Kalunian, M.D. is Professor of Medicine in the Division of

Rheumatology at the University of California, San Diego School of


-- David Wofsy, M.D. is Professor of Medicine and Microbiology/Immunology

at the University of California, San Francisco.

-- Debra Zack, M.D., Ph.D. is the Executive Director in Inflammation

Global Development at Amgen.

About AMG 623

AMG 623, which has completed Phase 1b studies in SLE patients, is a peptide fusion protein that binds to B-cell activating factor (BAFF). Anthera anticipates initiating Phase 2 studies in 2008. BAFF, a tumor necrosis factor family member, is critical for the survival and maturation of B cells. AMG 623 is a potent BAFF antagonist that is being developed as a treatment for B-cell dependent autoimmune diseases and is initially targeted for SLE.

About Anthera Pharmaceuticals

Anthera Pharmaceuticals is a privately-held company committed to developing and commercializing clinical pharmaceutical products that address unmet medical needs of patients with life-threatening, chronic and acute inflammatory and autoimmune diseases. The Company has acquired from Eli Lilly and Company and Shionogi & Co. Ltd. worldwide rights (excluding Japan) to a series of clinical and pre-clinical compounds that inhibit the enzymatic activity of members of the phospholipase A2 (PLA2) family -- a group of enzymes responsible for the release of arachidonic acid and subsequent production of leukotrienes prostacyclins and other mediators of inflammation. These highly potent compounds inhibit novel upstream steps in the inflammation cascade and have the potential to address a variety of diseases. The company has also acquired exclusive and worldwide rights to a peptide fusion protein, A-623, for the treatment of systemic lupus erythematosus (SLE) and other autoimmune diseases from Amgen. For more information, please visit

Investor and Media Contact:

Anne Bowdidge

(650) 218-6900

SOURCE Anthera Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. European EMEA Acceptance of Marketing Authorization Application Filing for SNT-MC17 in Friedreichs Ataxia by Santhera
2. Vion Pharmaceuticals Adds William Hahne, M.D. to Senior Management Team
3. Poniard Pharmaceuticals Appoints Robert De Jager, M.D., as Chief Medical Officer
4. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference on February 5, 2008 in New York
5. Amylin Pharmaceuticals to Present at Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
6. Koronis Pharmaceuticals Announces Appointment of Daniel H. Petree and George R. Painter, Ph.D. to Board of Directors
7. MiddleBrook Pharmaceuticals Closes Private Placement of Common Equity Raising $21 Million
8. Sagent Pharmaceuticals, Inc. to Present at Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
9. Access Pharmaceuticals Announces $2.7 Million New Equity
10. Ferring Pharmaceuticals Announces EUFLEXXA(TM) as Title Sponsor of the National Senior Games Hockey Championships and the GeezerJock of the Year Award
11. Alexion Pharmaceuticals Invites You to Participate in its Fourth Quarter and Full Year 2007 Results Conference Call and Web Cast
Post Your Comments:
(Date:11/24/2015)... ... November 24, 2015 , ... Copper ... unless it is bound to proteins, copper is also toxic to cells. With ... Worcester Polytechnic Institute (WPI) will conduct a systematic study of copper in the ...
(Date:11/24/2015)... 24, 2015 --> ... report "Oligonucleotide Synthesis Market by Product & Services (Primer, ... Diagnostic, DNA, RNAi), End-User (Research, Pharmaceutical & Biotech, Diagnostic ... the market is expected to reach USD 1,918.6 Million ... a CAGR of 10.1% during the forecast period. ...
(Date:11/24/2015)... New York , November 24, 2015 ... to a recent market research report released by Transparency ... projected to expand at a CAGR of 17.5% during ... "Non-invasive Prenatal Testing Market - Global Industry Analysis, Size, ... estimates the global non-invasive prenatal testing market to reach ...
(Date:11/24/2015)... ... November 24, 2015 , ... In harsh ... Insertion points for in-line sensors can represent a weak spot where leaking process ... series of retractable sensor housings , which are designed to tolerate extreme process ...
Breaking Biology Technology:
(Date:11/11/2015)... Minn. , Nov. 11, 2015   MedNet Solutions ... entire spectrum of clinical research, is pleased to announce that ... in Clinical Trials (PCT) event, to be held November ... be able to view live demonstrations of iMedNet ... and learn how iMedNet has been able to ...
(Date:11/4/2015)... November 4, 2015 --> ... report published by Transparency Market Research "Home Security Solutions Market ... Forecast 2015 - 2022", the global home security solutions market is ... by 2022. The market is estimated to expand at ... 2015 to 2022. Rising security needs among customers at ...
(Date:10/29/2015)... Oct. 29, 2015  Rubicon Genomics, Inc., today ... distribution of its DNA library preparation products, including ... new ThruPLEX Plasma-seq kit. ThruPLEX Plasma-seq has been ... of NGS libraries for liquid biopsies--the analysis of ... prognostic applications in cancer and other conditions. Eurofins ...
Breaking Biology News(10 mins):